Acarix Ab · OMXSTO:ACARIX
Acarix Ab — Q1 2026 Earnings Presentation
24 slides from Acarix Ab's earnings presentation, May 18, 2026
Slide 1: Acarix Q1 2026
Transforming Early Cardiac Diagnostics Acarix Q1 2026 Aamir Mahmood President & CEO 05/18/26
Slide 2: The CADScor System: Transforming Early Cardiac Diagnostics with Rapid Assessment
The CADScor®System Transforming Early Cardiac Diagnostics with Rapid Assessment A rapid, point of care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to calculate a patient specific CAD risk score Quickly and easily risk-stratify significant coronary artery
Slide 3: Executive Summary
q | Executive Summary
Slide 4: Continued Expansion and Progress in Q1
Continued Expansion and Progress in Q1 Q1 Commercial Performance ● Revenue increased 40% year over year to SEK 2,424 thousand, driven by 63% growth in the U.S. (90% currency-adjusted). ● 29 CADScor Systems delivered in the U.S. market, reflecting accelerating adoption. Financial Performance & Cost Di
Slide 5: CEO Message: Aamir Mahmood
The first quarter of 2026 marks a strong start to the year for Acarix, with revenue up 40% year-over-year, driven by 63% U.S. growth (90% currency-adjusted). Operating costs declined 32% and net loss improved 38%, reflecting a business increasingly balancing commercial execution with financial discipli
Slide 6: Q1 Highlights
Q1 Highlights q |
Slide 7: CADScor ACC.26 Data Demonstrates Strong Clinical and Operational Value
CADScor® ACC.26 Data Demonstrates Strong Clinical and Operational Value ● Abstract presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo (ACC.26), demonstrating high negative predictive value vs. standard stress tests in chest pain patients. ● Data indicates substant
Slide 8: CADScor System Receives EU MDR Certification
CADScor® System Receives EU MDR Certification ● EU MDR Certification Achieved for the CADScor® System, confirming CE marking in accordance with Regulation (EU) 2017/745 and demonstrating compliance with applicable EU safety, quality, and clinical performance requirements. ● Strengthens European Commerc
Slide 9: Creating a Scalable Pathway for Reimbursement
Creating a Scalable Pathway for Reimbursement ● Obtained coverage and reimbursement from SoonerCare (Oklahoma Medicaid) for the CADScor to be retroactive to 1/1/26. ● Consistent reimbursement in 2026 compared to 2025 with the Payers. ● Clinical Policy meetings with executive leadership with Blue Cro
Slide 10: 0716T Private Clinic Reimbursement
0716T Private Clinic Reimbursement Incl. Commercial & MA Cigna, Cigna Connect Commercial, GA, LA, IL, AZ Avg payment Avg payment Avg payment Average Reimbursement $350 $336 $289 $387 Federal Avg payment Avg payment Avg payment $403 $750 $300 As of August 2025, Cigna, Humana and United Healthcare NO
Slide 11: Marketing Highlights
Marketing Highlights LinkedIn ● LinkedIn generated 26.8K impressions and 5.8K engagements in Q1, with CTR increasing to 7.1%, reflecting stronger audience engagement with Acarix updates and thought leadership content. ● Research announcements, conference activity, and product-focused posts drove the
Slide 12: Q1 Financials
Q1 Financials 12
Slide 13: Q1 2026 Financial Highlights
Q1 2026 Financial Highlights U.S. CADScor U.S. Patch Operating Systems Sales Costs Delivered — — — Units Sold Units Sold 15% 32% 53% YoY Quarterly YoY Quarterly YoY Quarterly Revenue in the quarter increased 40% year-over-year, driven primarily by 63% growth in the U.S. (90% currency-adjusted), whil
Slide 14: U.S. CADScor System Installations Driving Recurring Patch Sales
U.S. CADScor® System Installations Driving Recurring Patch Sales U.S. CADScor System Installations U.S. Acoustic Patch Sales 14
Slide 15: Expanding U.S. Clinical Adoption Across Key Disciplines
Expanding U.S. Clinical Adoption Across Key Disciplines U.S. CADScor System Installations* Primary Care Driving Quarterly Growth Quarter growth was led by continued expansion within Primary Care, reflecting increasing physician adoption and broader integration into frontline cardiac assessment pathwa
Slide 16: Q1 Global Revenue
Q1 Global Revenue Revenue 2,424 +40% 1,729 Q1 2025 Q1 2026 Total revenue amounted to SEK 2,424 thousand (1,729), an increase of 40% (61% currency-adjusted) 16
Slide 17: Q1 U.S. CADScor Units Installed
Q1 U.S. CADScor Units Installed CADScor Units 29 +53% 19 Q1 2025 Q1 2026 A total of 29 systems were delivered and consigned during the period, all in the U.S. market. Of these, 25 were sold and 4 units were consigned. 17
Slide 18: Q1 U.S. Patch Sales
Q1 U.S. Patch Sales U.S. Patch Sales (boxes) 122 +15% 106 Q1 2025 Q1 2026 In the U.S., patch sales amounted to 122 boxes (106), an increase of 15% compared to the same quarter in 2025. 18
Slide 19: Q1 Global Gross Margin
Q1 Global Gross Margin Gross Margin 81% 81% Q1 2025 Q1 2026 Gross margin was 81%, consistent with 81% in Q1 2025, reflecting a stable product and channel mix. 19
Slide 20: Continued Cost Saving Initiatives
Continued Cost Saving Initiatives OPEX Reduction kSEK 15,437 10,421 -32% Q1 2025 Q1 2026 Operating costs totaled SEK 10,421 thousand, down 32% from SEK 15,437 thousand in Q1 2025, reflecting continued cost-saving initiatives and stronger operational efficiency. 20
Slide 21: Q1 Net Loss
Q1 Net Loss Net Loss kSEK -14,108 -8,781 38% Q1 2025 Q1 2026 Net loss improved 38% to SEK –8,781 thousand, compared to SEK –14,108 thousand in Q1 2025, reflecting disciplined execution. 21
Slide 22: Monthly Burn Rate
Monthly Burn Rate Monthly Burn Rate kSEK -3,889 -3,059 -21% Q1 2025 Q1 2026 22
Slide 23: Key Go-Forward Objectives
Key Go-Forward Objectives ● Expanding Rural Healthcare Opportunity ○ Continued efforts to participate in the Rural Health Transformation Program (RHTP), supporting broader access to frontline cardiac evaluation in underserved rural communities. ● Clinical Trials: ○ Systematic review of clinical tria
Slide 24: Thank You!
Transforming Early Cardiac Diagnostics Thank You! 24